The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, J. Y. | - |
dc.contributor.author | Hong, M. E. | - |
dc.contributor.author | Choi, M. K. | - |
dc.contributor.author | Kim, Y. S. | - |
dc.contributor.author | Chang, W. | - |
dc.contributor.author | Maeng, C. H. | - |
dc.contributor.author | Park, S. | - |
dc.contributor.author | Lee, S. J. | - |
dc.contributor.author | Do, I. -G. | - |
dc.contributor.author | Jo, J. -S. | - |
dc.contributor.author | Jung, S. H. | - |
dc.contributor.author | Kim, S. J. | - |
dc.contributor.author | Ko, Y. H. | - |
dc.contributor.author | Kim, W. S. | - |
dc.date.available | 2020-02-28T18:43:58Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2014-01 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12942 | - |
dc.description.abstract | Background: Oncogenic phosphatidylinositol-3-kinase/serine-threonine kinase (PI3K/AKT) pathway plays a critical role in cell proliferation and growth. Phosphorylated AKT (p-AKT) has been reported to be abnormally overexpressed and to have poor prognostic impact in solid tumors. Patients and methods: To define the clinical implications of p-AKT expression in diffuse large B-cell lymphoma (DLBCL), we calculated arbitrary units (AUs) by multiplying the intensity and the proportion of p-AKT expression and investigated the impact of p-AKT expression on clinical outcomes. We assessed 262 patients with DLBCL. Based on a cutoff value of the upper limit of the third quartile of AUs, 56 patients were classified as high p-AKT and the remaining 206 patients were classified as low p-AKT. Results: The high p-AKT group was closely associated with more advanced stage (stage III-IV, P = 0.02), two or more extranodal involvement (P = 0.03), lactic dehydrogenase elevation (P = 0.03), higher International Prognostic Index risk groups (high intermediate/high, P = 0.02), and the presence of B-symptoms (P = 0.01). The high p-AKT group showed substantially worse overall survival (OS) (median OS, 115.0 months versus not reached, P = 0.004) and progression-free survival (PFS) (median PFS, 25.5 versus 105.8 months, P = 0.019) compared with the low p-AKT group. Multivariate analysis revealed that high p-AKT expression retained its significant poor prognostic impact for OS (hazard ratio 1.7; 95% confidence interval, 1.0-2.7; P = 0.031). The subgroup with high p-AKT expression and concurrent Epstein-Barr virus positivity showed worst prognosis with the median OS and PFS of 15.2 and 7.4 months. Conclusion: DLBCL patients with high p-AKT expression showed distinct clinical features and followed a more rapidly deteriorating clinical course with worse OS and PFS. Thus, a more effective treatment option should be developed for this subset of DLBCL patients, and targeting PI3K/AKT pathway may be a promising therapeutic strategy. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
dc.subject | NON-HODGKIN-LYMPHOMA | - |
dc.subject | PHASE-II TRIAL | - |
dc.subject | PROGNOSTIC-SIGNIFICANCE | - |
dc.subject | HUMAN CANCER | - |
dc.subject | SURVIVAL | - |
dc.subject | INHIBITOR | - |
dc.subject | PATHWAY | - |
dc.subject | KINASE | - |
dc.subject | LEUKEMIA | - |
dc.subject | PROTEIN | - |
dc.title | The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000331268800029 | - |
dc.identifier.doi | 10.1093/annonc/mdt530 | - |
dc.identifier.bibliographicCitation | ANNALS OF ONCOLOGY, v.25, no.1, pp.182 - 188 | - |
dc.identifier.scopusid | 2-s2.0-84905406380 | - |
dc.citation.endPage | 188 | - |
dc.citation.startPage | 182 | - |
dc.citation.title | ANNALS OF ONCOLOGY | - |
dc.citation.volume | 25 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Kim, Y. S. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | diffuse large b-cell lymphoma | - |
dc.subject.keywordAuthor | PI3K/AKT pathway | - |
dc.subject.keywordAuthor | p-AKT | - |
dc.subject.keywordPlus | NON-HODGKIN-LYMPHOMA | - |
dc.subject.keywordPlus | PHASE-II TRIAL | - |
dc.subject.keywordPlus | PROGNOSTIC-SIGNIFICANCE | - |
dc.subject.keywordPlus | HUMAN CANCER | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | PATHWAY | - |
dc.subject.keywordPlus | KINASE | - |
dc.subject.keywordPlus | LEUKEMIA | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.